These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 22793021)
1. Meeting the demands of regulatory requirements: the significance of ADME. Guttendorf R Bioanalysis; 2012 Jun; 4(12):1395-7. PubMed ID: 22793021 [No Abstract] [Full Text] [Related]
2. Memo to the FDA and ICH: appeal for in vivo drug target identification and target pharmacokinetics Recommendations for improved procedures and requirements. Stumpf WE Drug Discov Today; 2007 Aug; 12(15-16):594-8. PubMed ID: 17706540 [TBL] [Abstract][Full Text] [Related]
3. The importance of HT-ADME in drug discovery. Morgan D Bioanalysis; 2011 Nov; 3(21):2385-7. PubMed ID: 22074279 [TBL] [Abstract][Full Text] [Related]
4. Strategies at the interface of drug discovery and development: early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates. Palucki M; Higgins JD; Kwong E; Templeton AC J Med Chem; 2010 Aug; 53(16):5897-905. PubMed ID: 20527889 [No Abstract] [Full Text] [Related]
5. The EMEA guideline on first-in-human clinical trials and its impact on pharmaceutical development. Milton MN; Horvath CJ Toxicol Pathol; 2009 Apr; 37(3):363-71. PubMed ID: 19246571 [No Abstract] [Full Text] [Related]
6. Requirements for a lead compound to become a clinical candidate. Hefti FF BMC Neurosci; 2008 Dec; 9 Suppl 3(Suppl 3):S7. PubMed ID: 19091004 [TBL] [Abstract][Full Text] [Related]
8. Recent advances in physicochemical and ADMET profiling in drug discovery. Wang J; Skolnik S Chem Biodivers; 2009 Nov; 6(11):1887-99. PubMed ID: 19937823 [TBL] [Abstract][Full Text] [Related]
9. Evolving molecules using multi-objective optimization: applying to ADME/Tox. Ekins S; Honeycutt JD; Metz JT Drug Discov Today; 2010 Jun; 15(11-12):451-60. PubMed ID: 20438859 [TBL] [Abstract][Full Text] [Related]
10. Beyond profiling: using ADMET models to guide decisions. Segall M; Champness E; Obrezanova O; Leeding C Chem Biodivers; 2009 Nov; 6(11):2144-51. PubMed ID: 19937845 [TBL] [Abstract][Full Text] [Related]
11. Strategies for conducting ADME studies during lead generation in the drug discovery process. Cramer JW; Mattioni BE; Savin KA IDrugs; 2010 Dec; 13(12):857-61. PubMed ID: 21154143 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic drug interaction studies must consider pharmacological heterogeneity, use of repeated dosing, and translation into a message understandable to practicing clinicians. de Leon J; Spina E; Diaz FJ J Clin Psychopharmacol; 2009 Jun; 29(3):201-5. PubMed ID: 19440070 [No Abstract] [Full Text] [Related]
13. The early estimation of circulating drug metabolites in humans. Luffer-Atlas D Expert Opin Drug Metab Toxicol; 2012 Aug; 8(8):985-97. PubMed ID: 22681256 [TBL] [Abstract][Full Text] [Related]
14. Re-engineering drug discovery and development. FitzGerald GA LDI Issue Brief; 2011 Oct; 17(2):1-4. PubMed ID: 22049582 [TBL] [Abstract][Full Text] [Related]
15. Bioanalysis in drug discovery. Hill H Bioanalysis; 2011 Oct; 3(19):2155-8. PubMed ID: 21985408 [No Abstract] [Full Text] [Related]
17. When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective. Huang SM; Temple R; Xiao S; Zhang L; Lesko LJ Clin Pharmacol Ther; 2009 Nov; 86(5):475-9. PubMed ID: 19844224 [TBL] [Abstract][Full Text] [Related]
18. Predicting human pharmacokinetics from preclinical data. Poggesi I Curr Opin Drug Discov Devel; 2004 Jan; 7(1):100-11. PubMed ID: 14982153 [TBL] [Abstract][Full Text] [Related]
19. How to avoid rediscovering the known. Kuo LC Methods Enzymol; 2011; 493():159-68. PubMed ID: 21371591 [TBL] [Abstract][Full Text] [Related]
20. The inspection of drug metabolism and pharmacokinetic studies. Dent NJ Qual Assur; 1992 Jun; 1(3):230-6. PubMed ID: 1344678 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]